- To stay updated on the relevant developments, make sure you are signed up for our newsletter.
Meeting category
Date(s)
20 Apr 2023
Program Language
English
Meeting type
Virtual
CME Credits
2
International Workshop on Monoclonal Antibodies for Treatment & Prevention of Infectious Diseases 2023
Related Enduring Materials
Enduring Materials
-
Pharmacological Consideration when using Monoclonal Antibodies for the Treatment and Prevention of Infectious Diseases: Implications for Ebola and Clostridium difficile
Prevention of RSV in Neonates
Monoclonal Antibodies for HIV—Lessons Learned from COVID-19
Monoclonal Antibodies for HIV Prevention
Panel Discussion
General
What's New
Image
Welcome
With more than 100 monoclonal antibiotics (mAbs) in use, harnessing this technology has advanced therapeutic development for COVID-19 and underscored their utility and versatility to respond rapidly to emerging global health threats.
Recent approvals and recommendations for mAbs in preventing and treating RSV and Ebola offer novel tools to control these (re) emerging viruses.
They also offer new avenues for preventing bacterial and parasitic infections, such as Clostridium difficile and Plasmodium falciparum (causative agent of malaria tropica in humans).
Those advances come hand-in-hand with educational needs to comprehend technology, pharmacological properties, challenges for equitable access, and recent clinical data.
In contrast to existing programs, this workshop provided a platform for cross-disciplinary discussion, catalyzed knowledge transfer, and prompted the discussions on remaining unknowns to ultimately move the field forward.
Program Directors
General Information
Uniques Features
- Clinical utility of monoclonal antibodies for IDs
- Interactive case presentations
- Cross-disciplinary discussion
- Interactive case presentations
- Cross-disciplinary discussion
Who Should Attend?
- Infectious disease doctors
- Researchers, microbiologists, virologists, immunologists
- Pharmacologists
- Nurses, pharmacists
- Healthcare administrators
- Policymakers, and (non)government representatives
- Researchers, microbiologists, virologists, immunologists
- Pharmacologists
- Nurses, pharmacists
- Healthcare administrators
- Policymakers, and (non)government representatives
Meeting Objectives
This meeting aims to:
- Provide a platform to summarize key data on the clinical utility of monoclonal antibodies for the prevention and treatment of infectious disease.
- Strengthen education on the monoclonal antibody-based therapeutics for infectious diseases among healthcare professionals, researchers, and policymakers.
- Stimulate cross-disciplinary discussion on the clinical relevance of monoclonal antibody-based therapeutics in the context of public health emergencies and rethinking the approaches for conditions that are currently challenging to treat or prevent.
- Provide a platform to summarize key data on the clinical utility of monoclonal antibodies for the prevention and treatment of infectious disease.
- Strengthen education on the monoclonal antibody-based therapeutics for infectious diseases among healthcare professionals, researchers, and policymakers.
- Stimulate cross-disciplinary discussion on the clinical relevance of monoclonal antibody-based therapeutics in the context of public health emergencies and rethinking the approaches for conditions that are currently challenging to treat or prevent.
Learning Objectives
After participating in this activity, participants will be able to:
- Summarize the latest clinical data on the use of monoclonal antibodies for the prevention and treatment of infectious diseases.
- Comprehend key clinical considerations for the use of monoclonal antibodies in different priority populations (e.g. pediatrics, immunocompromised patients).
- Discuss the impact of microbial molecular evolution on the clinical utility of monoclonal antibodies.
- Reflect on barriers and opportunities for equitable access to mAb-based therapeutics.
- Summarize the latest clinical data on the use of monoclonal antibodies for the prevention and treatment of infectious diseases.
- Comprehend key clinical considerations for the use of monoclonal antibodies in different priority populations (e.g. pediatrics, immunocompromised patients).
- Discuss the impact of microbial molecular evolution on the clinical utility of monoclonal antibodies.
- Reflect on barriers and opportunities for equitable access to mAb-based therapeutics.
Practical Information
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the program and post-meeting survey.
Language
The official language of the workshop is English
Translation will not be provided.
Translation will not be provided.
Enduring Materials
Enduring materials will be available shortly after the conclusion of the workshop.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Committees
Program Directors
Organizing Committee
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
Support
Silver Level
Contributor Level
Support Our Initiative
Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals and researchers interested in International Workshop on Monoclonal Antibodies for Treatment & Prevention of Infectious Diseases.
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
To show your commitment to the cause, get in touch with us for a tailored
support package by contacting Lara da Silva Miguel at Lara@amededu.com.
Benefits of Support
By supporting this program, we can offer the following advantages for your company.
* Please contact us for the most recent support level benefits for this program.
- Symposium opportunities
- Non-commercial interviews with company representatives
- Verbal acknowledgement during the program
- Discounted and complimentary registrations for your representatives
- Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
- Company acknowledgement on printed meeting materials including but not limited to banners and the program book
- Digital and printed advertising opportunities
- Social media shout-outs
- Logo on the conference bag
*Subject to the support level.
Accreditation
Accreditation Statement
The International Workshop on Monoclonal Antibodies for Treatment & Prevention of Infectious Diseases 2023, 20/04/2023-20/04/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 2 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Endorsers
Endorsers
International Workshop on Monoclonal Antibodies for Treatment & Prevention of Infectious Diseases is endorsed by societies and organizations. Their support and collaboration are key to the success of this meeting!
If you would like your organization to endorse this workshop, please contact Magda Sevlidou at magda.sevlidou@amededu.com.
Previous Editions
Top-Rated Materials from Previous Edition
Title: Monoclonal Antibodies for Treatment in HIV
Speaker: Marina Caskey, MD
Presented at Session 2: Clinical Development and Use - Infectious Diseases
Language
Related Programs
